Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Sch...(mory Pharmaceuticals' drug candidates; M...),Health

Date:11/19/2008

mory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Capital Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

'/>"/>

SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
2. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
3. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
4. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. How Big Is Your Brain? Its Size May Protect You from Memory Loss
8. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
11. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease